ストックスクリーナーアプリを入手
2.88
5.47%
0.14
Anavex Life Sciences Corporation (AVXL) 最新ニュース
AVXL Plummets 31% to 52-Week Lows: A Technical Meltdown Ignites the Biotech Watchlist - Bitget
Anavex Life Sciences withdraws EU marketing application for blarcamesine after CHMP feedback - TradingView
Anavex (NASDAQ: AVXL) withdraws EU Alzheimer’s drug application for blarcamesine - Stock Titan
Crude Oil Moves Lower; Cintas Raises FY2026 Forecast - Benzinga
Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings - Benzinga
Anavex Life Sciences Corp Faces Competitive Pressure Amid Financial Year Results - StocksToTrade
Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback - Benzinga
Anavex Life Sciences Corp. (AVXL) recently disclosed the latest updates on the regulatory review of its investigational drug Blarcamesine for early Alzheimer’s disease in the European Union. - Bitget
Anavex Life Sciences stock tumbles after EU filing withdrawal By Investing.com - Investing.com UK
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease - marketscreener.com
EU review halts Anavex’s Alzheimer’s drug bid, more data next - Stock Titan
Anavex Life lead drug targets early Alzheimer's causenew study highlights - MSN
AVXL Stock Soars After Anavex’s New Data Suggests Its Alzheimer’s Drug May Slow Brain Shrinkage - Stocktwits
D. Boral Capital Reiterates Buy Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease - The Manila Times
Study ties oral Alzheimer’s drug to slower brain shrinkage - Stock Titan
AVXL Technical Analysis | Trend, Signals & Chart Patterns | ANAVEX LIFE SCIENCES CORP (NASDAQ:AVXL) - ChartMill
Anavex Life Lead Drug Targets Early Alzheimer's CauseNew Study Highlights - Sahm
Form 8K Anavex Life Sciences Corp For: 9 February - Investing.com
Anavex Life Sciences Announces New Study Linking Autophagy Dysfunction to Alzheimer’s Disease Pathology - Quiver Quantitative
New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease - The Manila Times
Alzheimer’s study points to cell-cleanup failure before plaques form - Stock Titan
AVXL Stock Price, Quote & Chart | ANAVEX LIFE SCIENCES CORP (NASDAQ:AVXL) - ChartMill
Anavex Life Sciences Reports Positive Data for Blarcamesine in New Parkinson’s Disease Model at AD/PD™ 2026 Conference - Quiver Quantitative
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference - The Manila Times
Parkinson’s therapy hope: blarcamesine regrows nerve fibers in lab model - Stock Titan
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Crosses Above 50 Day Moving AverageTime to Sell? - MarketBeat
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's - MSN
Anavex Life Sciences Stock Rises After Experimental Alzheimer’s Drug Slows Cognitive Decline In Study - MSN
AVXL SEC FilingsAnavex Life Scie 10-K, 10-Q, 8-K Forms - Stock Titan
Earnings Update: Is Anavex Life Sciences Corp a top pick in the sectorM&A Rumor & Fast Gaining Stock Reports - baoquankhu1.vn
Anavex Life Sciences Touts Oral Alzheimer’s Drug Blarcamesine Data, Cash Runway at Healthcare Conference - Yahoo Finance
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Passes Above Fifty Day Moving AverageWhat's Next? - MarketBeat
What's Going On With Anavex Life Sciences Stock On Wednesday? - Benzinga
Anavex Life Sciences to Present at the Citizens Life Sciences Conference - Anavex Life Sciences
Alzheimer's-focused Anavex CEO to speak at Citizens Life Sciences Conference - Stock Titan
Anavex Life Sciences Corp. (AVXL): Investor Outlook on a Biotechnology Stock with a Potential 393% Upside - DirectorsTalk Interviews
Anavex Adds Veteran Healthcare Leader to Board of Directors - The Globe and Mail
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference - Bitget
Anavex Life Sciences Corp. CEO to Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026 - Quiver Quantitative
Alzheimer’s treatment developer Anavex to speak at TD Cowen health conference - Stock Titan
Anavex Life Sciences (NASDAQ:AVXL) Shares Cross Below 50-Day Moving AverageHere's What Happened - MarketBeat
EBITDA per share of Anavex Life Sciences Corp. – LSE:0HFR - TradingView
Anavex Life Sciences appoints Dr. Axel Paeger to board By Investing.com - Investing.com India
Anavex Life Sciences appoints Dr. Axel Paeger to board - Investing.com
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors - marketscreener.com
Anavex Life Sciences Corp. (AVXL) Stock Analysis: Unveiling a Remarkable 433.98% Potential Upside - DirectorsTalk Interviews
Why analysts upgrade Anavex Life Sciences Corp. stockAnalyst Upgrade & AI Powered Buy/Sell Recommendations - mfd.ru
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update - Anavex Life Sciences
Anavex Life Sciences (NASDAQ:AVXL) Upgraded at Wall Street Zen - MarketBeat
0.99%
3.03%
大文字化:
|
ボリューム (24 時間):